Foghorn Therapeutics Updates Its Groundbreaking Oncology Programs
Foghorn Therapeutics Inc. (NASDAQ: FHTX), a pioneering biotechnology firm based in Cambridge, is making noteworthy strides in oncology. Recently, the company presented data demonstrating the progress of their innovative Selective ARID1B, Selective CBP, and Selective EP300 degrader programs at an esteemed summit. This news positions Foghorn as a leader in the development of therapies that correct abnormal gene expression, addressing some of the most challenging targets in cancer treatment.
Selective ARID1B Degrader: A Promising New Therapy
Recent advancements show that Foghorn's Selective ARID1B degrader effectively binds to and degrades the ARID1B protein, a vital target in up to 5% of solid tumors. Notably, mutations in genes often lead to dependencies on ARID1B, particularly in endometrial, gastric, gastroesophageal junction, bladder, and non-small cell lung cancers. The challenge has always been the high homology between ARID1A and ARID1B, making selective targeting difficult. However, the preclinical data presented highlights remarkable progress in overcoming these hurdles.
Key Developments in ARID1B Degradation
Foghorn's approach utilizes bifunctional degraders designed with the potential for oral delivery. These developments denote a significant scientific breakthrough, marking the first achievements in selective degradation of ARID1B. The current objective is to advance the program towards proof of concept studies planned for 2026.
Progress on Selective CBP Degrader
Turning to the Selective CBP degrader, this program has substantial implications, especially in cancers with EP300 mutations, including various solid tumors. The Selective CBP degrader is progressing steadily, with a timeline set for non-GLP toxicology studies in the upcoming quarter. This degrader shows promise not only in terms of efficacy but also in safety profiles over existing dual-target therapies affecting both CBP and EP300.
Highlights from the CBP Program
The lead candidate, CBPd-171, is proving highly potent and selective, showing significant anti-tumor activity in EP300-mutant cancers, especially in ER+ breast cancer. Moreover, the formulation is designed for easy administration, optimizing the dosing schedule for utmost patient convenience.
Innovations in Selective EP300 Degrader Program
The Selective EP300 degrader program is gaining momentum, primarily focusing on hematological malignancies such as multiple myeloma and diffuse large B-cell lymphoma. By addressing the challenges associated with dual inhibition of CBP and EP300, Foghorn’s development of a selective EP300 degrader is particularly exciting.
Promising Early Results
Preclinical trials have already demonstrated broad anti-tumor activity in over 70% of hematological cancer sublineages tested. Furthermore, the selective EP300 degrader has shown efficacy even in IMiD-resistant multiple myeloma cell lines, emphasizing its potential as a new contender in cancer treatment innovation.
About Foghorn Therapeutics
Foghorn Therapeutics is at the forefront of a novel approach to drug development, centering on genetically determined dependencies within the chromatin regulatory system. With its unique Gene Traffic Control® platform, the firm systematically studies and identifies drug targets that could revolutionize cancer treatments. The commitment to advancing multiple oncology product candidates signifies Foghorn's dedication to fostering breakthroughs in healthcare.
Frequently Asked Questions
What is the focus of Foghorn Therapeutics' recent announcements?
The announcements highlight advancements in the company's Selective ARID1B, CBP, and EP300 degrader programs in oncology.
When is Foghorn Therapeutics expecting to achieve proof of concept for their ARID1B degrader?
They are aiming for in vivo proof of concept studies in 2026.
What benefits does the Selective CBP degrader offer compared to traditional therapies?
The Selective CBP degrader shows promising efficacy with a lower risk of dose-limiting toxicities often associated with dual inhibition treatments.
What populations could benefit from the Selective EP300 degrader?
This program primarily targets patients with hematological malignancies, such as multiple myeloma and diffuse large B-cell lymphoma.
How is Foghorn Therapeutics positioning itself in the biotechnology sector?
With its innovative drug discovery techniques and commitment to addressing challenging cancer targets, Foghorn is establishing itself as a leader in targeted protein degradation.
